Editor-in-Chief: Alex A. Adjei, MD, PhD, FACP
ISSN: 1556-0864
Online ISSN: 1556-1380
Frequency: 12 issues / year
Ranking: Oncology 30/211, Respiratory System 7/57
Impact Factor: 5.282
Editor's Choice

The articles highlighted in the August issue of the Journal of Thoracic Oncology address different aspects of lung cancer and remind us of the complexity of this disease. Invasive mucinous adenocarcinoma of the lung is a rare subtype. Shim et al have evaluated the genetic profile of 72 of these tumors, and have described their clinical characteristics as well, in “Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung”, Shim et al. There is an excellent accompanying editorial by Davies et al. In the paper “Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small cell lung cancer with activating EGFR mutation”, Keam et al used whole-body 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography scans in 75 patients with NSCLC tumors harboring EGFR mutations and receiving first-line gefitinib to create a predictive algorithm for clinical response. Drs Gold and Erasmus provide an insightful accompanying editorial. Finally, Verstegen et al report on the incidence and salvage of local recurrences and second primary lung cancers in 855 patients treated with stereotactic ablative radiotherapy. These patients had a long follow up with a median of 52 months, and the authors have generated data for evidence- based follow-up regimens. Alex A. Adjei, MD, PhD, Editor-in-Chief

Actions
View
  • Open Access
  • Free Access
  • Purchase Access
  • Partial Access
Actions
View
Login

Quick Poll

For coverage of this subject, please see Boland JM et al, J Thorac Oncol, 8: 574 -581, 2013

A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
 Submit
 Clear
 Results
Foreign Language Editions

JTO is proud to present translations of its content into French and Chinese. We sincerely thank  Jean-Louis Pujol, Wu Yilong, and Tony Mok for their work on the French and Chinese editions.  

French, Selected Articles

French JTO, Vol 1 Issue 1

French JTO, Vol 1 Issue 2

French JTO, Vol 1 Issue 3

 

Chinese, Selected Articles

Chinese JTO, Vol 2 Issue 2

 

Call for Videos
JTO accepts videos as supplemental content to articles. Submission guidelines online.
Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.